Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-08-02 Oral anticoagulants
| Rivaroxaban with aspirin |
|
Formulary
|
Tablets 2.5mg Prevention of cardiac events in patients with coronary (CAD) or peripheral artery Disease (PAD)
|
 LSCMMG: Rivaroxaban with aspirin MHRA: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial MHRA: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
|
| Warfarin |
|
Formulary
|
Tablets 1mg, 3mg, 5mg
|
 LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease MHRA: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR MHRA: Warfarin: be alert to the risk of drug interactions with tramadol MHRA: Warfarin: reports of calciphylaxis |
|
|
Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
| Andexanet alfa Ondexxya® |
|
Formulary
|
Powder for solution for infusion 200mg |
|
LSCMMG - Andexanet alfa NICE TA697- Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban |
|
| Idarucizumab® Praxbind |
|
Formulary
|
Solution for injection/infusion 2.5 g/50 mL
|
|
LSCMMG: Idarucizumab NMR |
|
|
Links
Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**- Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
- LSCMMG - Andexanet alfa
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Atrial Fibrillation: Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Idarucizumab NMR
- LSCMMG: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia: Position Statement
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Low Molecular Weight Heparins (LMWHs) Summary Prescribing Guide
- LSCMMG: Rivaroxaban 10mg tablets
- LSCMMG: Rivaroxaban with aspirin
- MHRA: Clopidogrel and proton pump inhibitors: interaction—updated advice
- MHRA: Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart valve(s) requiring anti-coagulant treatment
- MHRA: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR
- MHRA: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome
- MHRA: Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment
- MHRA: Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment
- MHRA: Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents
- MHRA: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼)
- MHRA: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial
- MHRA: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial
- MHRA: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food
- MHRA: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food
- MHRA: Warfarin: be alert to the risk of drug interactions with tramadol
- MHRA: Warfarin: reports of calciphylaxis
- NG 185 - Acute coronary syndromes
- NG 196 - Atrial fibrillation: diagnosis and management
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG158: Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG89: Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
- NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
- NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
- NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
- NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
- NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
- NICE TA275: Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
- NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
- NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
- NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
- NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
- NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
- NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
- NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
- NICE TA697- Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
- Renal: Enhanced Supportive Kidney Care Guideline